unknown
Stage
About
Dendreon develops and manufactures cellular immunotherapies, including Provenge, the first FDA-approved cellular immunotherapy for prostate cancer.
Explore Dendreon's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.